Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Labenz

Showing results (141-150 of 172) with videos related to

Pageof 18
Sort By:
Gastroenterology|March 1, 1996
Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcerJ Labenz, B Tillenburg, U Peitz, et al.
Alimentary Pharmacology & Therapeutics|February 3, 2009
Health-related quality of life in patients with gastro-oesophageal reflux disease under routine care: 5-year follow-up results of the ProGERD studyM Nocon, J Labenz, D Jaspersen, et al.
Zeitschrift Fur Gastroenterologie|December 9, 2003
Impact of reflux disease on general and disease-related quality of life - evidence from a recent comparative methodological study in GermanyA Madisch, K R Kulich, P Malfertheiner, et al.
Zeitschrift Fur Gastroenterologie|July 22, 1999
[Prevention of stomach carcinoma by Helicobacter pylori eradication. Invitation to participate in the PRISMA Study]E Bayerdörffer, S Miehlke, J Labenz, et al.
Scandinavian Journal of Gastroenterology|August 1, 1997
Focal inflammatory infiltrations in gastric biopsy specimens are suggestive of Crohn's disease. Crohn's Disease Study Group, GermanyA Meining, E Bayerdörffer, E Bastlein, et al.
Alimentary Pharmacology & Therapeutics|January 21, 2006
Cost-of-disease analysis in patients with gastro-oesophageal reflux disease and Barrett's mucosaS N Willich, M Nocon, M Kulig, et al.
Deutsche Medizinische Wochenschrift (1946)|May 8, 2004
[Short guideline for the management of dyspepsia]B Birkner, J Hotz, J Labenz, et al.
Alimentary Pharmacology & Therapeutics|February 28, 2002
High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized studyUlrich Peitz, M Sulliga, K Wolle, et al.
Alimentary Pharmacology & Therapeutics|February 27, 2009
Clinical course of laryngo-respiratory symptoms in gastro-oesophageal reflux disease during routine care--a 5-year follow-upD Jaspersen, M Nocon, J Labenz, et al.
Zeitschrift Fur Gastroenterologie|April 6, 1999
Prevalence and clinical importance of Helicobacter pylori infection in patients after partial gastric resection for peptic ulcer disease. A prospective evaluation of Helicobacter pylori infection on 50 resected patients compared with matched nonresected controlsD Schilling, H E Adamek, J Wilke, et al.
Pageof 18

Showing results (141-150 of 172) with videos related to

Sort By:
Pageof 18
Gastroenterology|March 1, 1996
Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcerJ Labenz, B Tillenburg, U Peitz, et al.
Alimentary Pharmacology & Therapeutics|February 3, 2009
Health-related quality of life in patients with gastro-oesophageal reflux disease under routine care: 5-year follow-up results of the ProGERD studyM Nocon, J Labenz, D Jaspersen, et al.
Zeitschrift Fur Gastroenterologie|December 9, 2003
Impact of reflux disease on general and disease-related quality of life - evidence from a recent comparative methodological study in GermanyA Madisch, K R Kulich, P Malfertheiner, et al.
Zeitschrift Fur Gastroenterologie|July 22, 1999
[Prevention of stomach carcinoma by Helicobacter pylori eradication. Invitation to participate in the PRISMA Study]E Bayerdörffer, S Miehlke, J Labenz, et al.
Scandinavian Journal of Gastroenterology|August 1, 1997
Focal inflammatory infiltrations in gastric biopsy specimens are suggestive of Crohn's disease. Crohn's Disease Study Group, GermanyA Meining, E Bayerdörffer, E Bastlein, et al.
Alimentary Pharmacology & Therapeutics|January 21, 2006
Cost-of-disease analysis in patients with gastro-oesophageal reflux disease and Barrett's mucosaS N Willich, M Nocon, M Kulig, et al.
Deutsche Medizinische Wochenschrift (1946)|May 8, 2004
[Short guideline for the management of dyspepsia]B Birkner, J Hotz, J Labenz, et al.
Alimentary Pharmacology & Therapeutics|February 28, 2002
High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized studyUlrich Peitz, M Sulliga, K Wolle, et al.
Alimentary Pharmacology & Therapeutics|February 27, 2009
Clinical course of laryngo-respiratory symptoms in gastro-oesophageal reflux disease during routine care--a 5-year follow-upD Jaspersen, M Nocon, J Labenz, et al.
Zeitschrift Fur Gastroenterologie|April 6, 1999
Prevalence and clinical importance of Helicobacter pylori infection in patients after partial gastric resection for peptic ulcer disease. A prospective evaluation of Helicobacter pylori infection on 50 resected patients compared with matched nonresected controlsD Schilling, H E Adamek, J Wilke, et al.
Pageof 18